Registry Study Offers Reassurance About Newer Drug-Eluting Stents — Physician’s First Watch
Registry Study Offers Reassurance About Newer Drug-Eluting Stents
By Larry Husten
Findings from a large ongoing registry study provide some reassurance about the long-term safety of new-generation drug-eluting stents (DES) in patients with ST-segment-elevation MI who undergo primary PCI. The results appear online in the Journal of the American College of Cardiology.
Swedish investigators analyzed data from 34,000 primary PCI patients who received a bare-metal stent (BMS), an old-generation DES, or a new-generation DES. They found that in the first year after PCI, rates of stent thrombosis were lower among both new- and old-generation DES patients (0.9% and 1.1%, respectively) than among BMS patients (1.5%). At 3 years, cumulative thrombosis rates were 1.3% with new-generation DES, 2.1% with old-generation DES, and 2.0% with BMS.
Editorialists write that the findings "are reassuring and should mitigate concerns about late and very late [stent thrombosis] with second-generation DES in STEMI patients."
Adapted from CardioExchange.
Note: The study and editorial have not yet been posted to the journal's website (although the embargo lifted on June 30). Below, we link to JACC's online-first page, where the articles should eventually appear.